Fig. 4.

Contribution of different genomic variant types to the important driver events underpinning different cancer types. Analysis of the cancer CORE set of relevant genes. Note: due to the diverse targets, not all of which are covered in this analysis, the contribution of fusions will be under-estimated in the sarcoma profile; no FGFR fusions were detected in the biliary tract samples which is likely due to the lower prevalence of these alterations in East Asia (cohort origin: Singapore). SV: disruptive structural variant; mutation: single nucleotide variants and indels; NET: neuroendocrine tumour. Cancer type [number of samples]: colorectal [52], thyroid [48], endometrial [44], bladder [23], melanoma [107], NSCLC [84], hepatocellular [336], head & neck [56], cervical [20], biliary tract [12], gastric [68], pancreatic adeno [232], CNS [287], oesophageal [97], breast [211], renal [186], pancreatic-NET [81], ovarian [110], prostate [199], bone [61], sarcoma [34].